Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Anal Cancer
Interventions
DRUG

Capecitabine

825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.

DRUG

Oxaliplatin

50 mg/m\^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.

RADIATION

Radiation Therapy (XRT)

Undergo radiotherapy\* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. \*Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.

Trial Locations (1)

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00093379 - Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer | Biotech Hunter | Biotech Hunter